Tembexa (brincidofovir oral) / SymBio Pharma, Jazz - LARVOL DELTA

Assessment of combined antiviral drug treatment against selected α-, β-, and γ-herpesviruses. (PubMed, Virol J) - "The single-drug antiviral treatments identified mean effective concentrations in the micromolar range, for abemaciclib (ABE) and the pharmacophore compound 020 (P-020), as well as submicromolar to nanomolar range, for brincidofovir (BCV) and cyclin-dependent kinase inhibitor of CDK7 (LDC4297). Thus, the study provides new information about antiherpesviral potency and characteristics of a selection of four antiviral prototype inhibitors. Especially, examples of broadness in synergistic combination treatment suggested options to improve antiherpesviral therapy strategies."

Journal • Epstein-Barr Virus Infections • Infectious Disease • CDK7

Erratum for Chou et al., "Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance". (PubMed, Antimicrob Agents Chemother) - No abstract available

Journal • Preclinical • Cytomegalovirus Infection

The evolution of tecovirimat resistance in an immunocompromised individual with severe mpox infection. (PubMed, Diagn Microbiol Infect Dis) - "Susceptibility to cidofovir and brincidofovir was preserved, and initiation of cidofovir was associated with clinical improvement and cessation of new lesions. This case demonstrates rapid intra-host evolution of multi-lineage tecovirimat resistance in severe mpox, highlighting the need for resistance surveillance and alternative or combination antiviral strategies in immunocompromised patients."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Seminal fluid enhances monkeypox virus infection via amyloidogenic fibrils. (PubMed, Emerg Microbes Infect) - "SEVI increased virion attachment and uptake, and fibril-targeting molecular tweezer (CLR01) disrupted seminal amyloids and abrogated enhancement. Notably, tecovirimat and brincidofovir retained activity under SEVI-enhanced conditions. These findings identify seminal amyloids as host factors that amplify MPXV infectivity and broaden cell tropism, suggesting that semen actively promotes sexual transmission of mpox."

Journal • Infectious Disease

Acid sphingomyelinase is an age-dependent host cell factor for adenovirus entry and a pharmacological target for synergistic combination therapy with brincidofovir. (PubMed, Biomed Pharmacother) - "Pharmacological inhibition of ASM by functional inhibitors such as fluoxetine resulted in a dose-dependent suppression of viral replication and significantly reduced infection rates in single-cycle infection assays, indicating disruption of early stages of the viral life cycle. These findings demonstrate that targeting host-controlled endosomal entry pathways can potentiate the antiviral efficacy of direct-acting agents. Together, our study validates ASM as a central regulator of HAdV entry and identifies combined host- and virus-directed therapy as a promising strategy to suppress HAdV infection."

Journal • Infectious Disease

An integrated review of monkeypox: from pathogen and epidemiology to diagnostics, control, and challenges. (PubMed, Emerg Microbes Infect) - "Although smallpox-related drugs (such as tecovirimat, cidofovir, and brincidofovir) show potential, their clinical efficacy needs to be verified. Prevention and control rely on a stronger monitoring system, timely risk warnings, and public health education. This article reviews the recent progress in MPXV detection, vaccine development, and antibody-based therapy, providing new insights for mpox prevention and control."

Journal • Review • Infectious Disease

Tracking the Trail of Monkeypox: From Origins to Outbreak Control. (PubMed, Cell Biochem Funct) - "Furthermore, it examines current challenges in disease detection and control and identifies opportunities to strengthen surveillance, prevention, and treatment strategies. Overall, this article aims to serve as a consolidated resource on MPXV, highlighting its epidemiology, clinical significance, and implications for global public health preparedness."

Journal • Review • Infectious Disease

A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review. (PubMed, Health Sci Rep) - "A large portion of this review is also devoted to assessing the efficacy and safety of investigational antiviral medicines like cidofovir and brincidofovir. The lack of specialized antiviral therapies for mpox is a huge gap in our medical arsenal. However, continuous research into new medications provides a glimpse of optimism."

Journal • Infectious Disease

Preclinical efficacy of the anti-EBV agent brincidofovir (BCV) in EBV-associated gastric carcinoma (EBVaGC). (ASCO 2026) - "Specifically, mice received intraperitoneal administration of vehicle, BCV, pembrolizumab (Pembro), or Pembro+BCV... BCV induced both dsDNA breaks and ICD in SNU-719 cells, similar to the positive control bleomycin... EBV is an oncovirus and its gene product EBNA1 is an oncoprotein for EBVaGC. This study showed a significant reduction of EBNA1 mRNA expression by BCV. Therefore, in addition to its own anti-tumor effects, BCV may contribute significantly to the suppression of EBVaGC tumorigenesis via its anti-EBV activity."

IO biomarker • Preclinical • Gastric Cancer • Head and Neck Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CALR • PD-L1

Immunity-oriented drug strategies for viral encephalitis: Acyclovir, antiepileptics and corticosteroids in neurological intensive care. (PubMed, Pak J Pharm Sci) - "Emerging therapies, including novel antivirals (favipiravir, remdesivir, brincidofovir), monoclonal antibodies, cytokine inhibitors (tocilizumab, anakinra) and B-cell/plasma cell-targeted agents (rituximab, daratumumab), offer promise by simultaneously addressing viral replication and immune dysregulation. Personalized biomarker-guided integrating pathogen-directed and host-targeted therapies may optimize outcomes, reduce neuronal injury and improve recovery. This review underscores the importance of a multidimensional, immunity-oriented treatment paradigm, highlighting both established and emerging strategies to enhance prognosis and long-term neurological functions in patients with viral encephalitis."

Journal • Review • CNS Disorders • Critical care • Epilepsy • Herpes Simplex • Herpes Zoster • Infectious Disease • Inflammation • Varicella Zoster

In Vitro Selection and Characterization of Tecovirimat-resistant Mpox Virus. (PubMed, J Infect Dis) - "These findings provide insights into the phenotype of each VP37 mutation and emphasize the importance of developing antivirals with distinct mechanisms of action to effectively combat tecovirimat-resistant MPXV."

Journal • Preclinical

[Mpox virus (MPXV) DNA replication machinery: Structural mechanisms and antiviral targets]: A review. (PubMed, Int J Biol Macromol) - "Although cidofovir and brincidofovir remain limited by safety concerns, most next-generation inhibitors are still at the preclinical stage. Future efforts should prioritize target validation, combination therapy optimization, and resistance surveillance to support safer and more effective anti-MPXV therapeutics."

Journal • Review • PCNA • RPA1

Tecovirimat for the treatment of monkeypox: A review of clinical trials. (PubMed, Przegl Epidemiol) - "The aim of this study was to identify clinical trials from the last 10 years evaluating the potential efficacy of tecovirimat, brincidofovir, and cidofovir in treating mpox infection, using the PubMed and ClinicalTrials.gov databases. The STOMP and PALM007 trials did not demonstrate a benefit of tecovirimat in patients with mpox, while studies conducted in Italy and Japan indicate clinical efficacy of the drug. Given the inconclusive clinical evaluation of tecovirimat so far, the results of ongoing studies are awaited and should provide further evidence to better assess the role of tecovirimat in the pharmacotherapy of mpox."

Clinical • Journal • Review • CNS Disorders • Infectious Disease • Pain • Pneumonia • Respiratory Diseases • Septic Shock

On topological co-index polynomials for predictive modeling of the physicochemical properties of antiviral drugs. (PubMed, Sci Rep) - "For an in-depth Quantitative Structure-Property Relationship (QSPR) analysis, we develop and compute topological co-indices using CoM and CoNM polynomials derived from the molecular structures of antiviral drugs, including Galidesivir, Chloroquine, Favipiravir, Amodiaquine, Azithromycin, Brincidofovir, and Clomiphene. To sum up, this study highlights the potential of topological co-indices as innovative tools for speeding up the discovery and optimization of antiviral drugs, especially concerning Ebola virus disease. The findings contribute to the expanding research focused on using computational methods to tackle emerging infectious diseases."

Journal • Ebola Virus Disease • Infectious Disease

Mpox in South Asia: A Narrative Review on Epidemiology, Preparedness, and Preventive Strategies. (PubMed, Health Sci Rep) - "Several antiviral agents are undergoing investigation, including cidofovir, brincidofovir, and so forth...Tecovirimat did not significantly reduce the time required to heal Mpox lesions in two separate studies...Strengthening vaccination, antiviral management, and diagnostic capacity is crucial to control transmission. Tailored region-specific strategies, including surveillance and stigma reduction, are essential."

Journal • Infectious Disease

Lack of Resistance Development during Brincidofovir Therapy in Animal Models of Orthopoxvirus Infection. (PubMed, Antiviral Res) - "No previously identified viral DNA polymerase BCV or cidofovir RAS were detected at or above 1% frequency in the RPXV or ECTV samples by NGS. Several novel mutations were identified in mouse ECTV samples; however, none, when introduced into VACV, conferred BCV resistance in a plaque reduction assay. In conclusion, no BCV resistance-associated mutations were detected in either animal model under the conditions of this treatment regimen."

Journal • Preclinical • Infectious Disease

Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways. (PubMed, Emerg Microbes Infect) - "Combination administration of lactoferrin with brincidofovir or tecovirimat demonstrated additive efficacy, suggesting a potential clinical strategy to reduce individual drug toxicity. These results underscore lactoferrin's distinctive dual antiviral mechanism and highlight its translational potential as a safe and cost-effective prophylactic or therapeutic agent. It is particularly beneficial for immunocompromised populations in resource-limited settings during orthopoxvirus outbreaks."

Journal • Infectious Disease • TGFB1 • TGFBI

The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges. (PubMed, Front Cell Infect Microbiol) - "We evaluate current diagnostic standards, such as PCR, alongside emerging techniques, and assess the efficacy of antiviral therapies, including tecovirimat, brincidofovir, and cidofovir. The status of vaccination, from second-generation (ACAM2000) to third-generation (MVA-BN and LC16m8) platforms, is critically appraised for its role in outbreak control. Furthermore, we explore the successes and hurdles of public health strategies, including surveillance, contact tracing, and community engagement, in managing stigma and ensuring equity. The review concludes by outlining future perspectives, emphasizing the urgent need for enhanced surveillance, accessible countermeasures, and research into broad-spectrum antivirals and vaccines to prepare for the ongoing threat of MPXV."

Journal • Review

Monkeypox Infection In Kidney Transplant Recipients： A Narrative Review. (PubMed, Kidney Blood Press Res) - "Monkeypox infection is spreading fast over the world and presents a major concern to kidney transplant recipients. In this immunocompromised group, we should focus more on effective preventative and treatment techniques. Further research is needed to standardize management algorithms."

Journal • Review • Infectious Disease • Pain • Pulmonary Disease • Transplantation

Insights into Monkeypox Virus: Host Immunity, Viral Immune Evasion, Recent Advances in Vaccines, Therapeutic Development, and Future Perspectives. (PubMed, Microorganisms) - "Alternative drugs like tecovirimat and brincidofovir have demonstrated potential for treating smallpox, but there is scanty evidence on their efficacy against MPXV. Most recent advancements in the study of vaccines have resulted in the creation and introduction of MVA-BN (JYNNEOS/Imvanex/Imvamune) and ACAM2000 vaccines, which conferred cross-protection against MPXV...The discovery of novel vaccine candidates and antiviral treatments will be needed to prevent future outbreaks and reduce the global health burden of Mpox. This review focuses on the characterization of MPXV, summarizing current knowledge on its genomic structure, pathogenesis, replication, potential targets of anti-MPXV drugs, clinical features, and epidemiological patterns, along with recent advances in vaccine development."

Journal • Review • Infectious Disease • Novel Coronavirus Disease

Pathogenicity and antiviral treatment of Clade Ib Monkeypox virus infection in mice. (PubMed, Antiviral Res) - "Here we describe the development of a lethal mouse model for clade Ib MPXV infection and its successful treatment using approved antivirals. Our results suggest that tecovirimat, cidofovir and brincidofovir remain suitable therapeutic options to treat clade Ib MPXV infection."

Journal • Preclinical • Infectious Disease

Eculizumab Is Associated with Significantly Lower Adenovirus Clearance in Children after Hematopoietic Cell Transplantation (TCT-ASTCT-CIBMTR 2026) - " Among 25 children with adenoviremia, the first adenovirus PCR was detected a median of 62 days post-HCT, Treatment approaches included cidofovir (76%), reduction of immune suppression (32%), viral specific T cells (20%), and brincidofovir (8%)- all ecu exposed patients received ≥1 treatment and 50% of non-ecu exposed received ≥1 treatment...In bivariable models adjusting for alemtuzumab (HR 0.26, p=0.02), abatacept (HR 0.14, p=0.001), post-HCT cyclophosphamide (HR 0.28, p=0.02), grade 3-4 acute GVHD (HR 0.20, p=0.02), and absolute lymphocyte count at first adenovirus PCR (HR 0.29, p=0.02), adenovirus clearance remained significantly lower in than those exposed to ecu... In this single center retrospective study, eculizumab exposed children were 3 times less likely to clear adenovirus and 6 times more likely to die of adenovirus related mortality. While these findings need to be validated in larger cohorts, our findings merit a careful risk/benefit analysis prior to..."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation • Transplantation Associated Thrombotic Microangiopathy

Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma. (PubMed, BMC Med) - "Taken together, these results demonstrate a novel role for BCV in lymphoma therapy and suggest potential for combination with checkpoint immunotherapy."

IO biomarker • Journal • Preclinical • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • PD-L1

Assessment of three antiviral compounds against Borealpox virus infection in a mouse model. (PubMed, Emerg Microbes Infect) - "Notably, extensive fluid retention was also observed in these mice. Further assessment of cidofovir, brincidofovir, and tecovirimat therapy against BRPV infection demonstrated that all three compounds resulted in improved clinical condition and significant reductions in BRPV titers."

Journal • Preclinical • Infectious Disease

The Emerging Threat of Monkeypox: An Updated Overview. (PubMed, Viruses) - "Therapeutic options remain limited; supportive care is the cornerstone of management, but antivirals such as tecovirimat and brincidofovir, as well as smallpox vaccines, have shown efficacy in mitigating disease severity and preventing infection. We also discuss the role of animal reservoirs, viral evolution, and human-to-human transmission in shaping the dynamics of recent MPOX outbreaks. By summarizing the latest evidence, this review aims to inform clinicians, researchers, and policymakers about key aspects of MPOX biology, clinical management, and prevention, while identifying gaps that warrant future investigation for the control of this and potentially other emerging zoonotic-related pathogens with an impact on human health."

Journal • Review • Infectious Disease • Varicella Zoster